Abbott Cert. Bid Says Nixing Pay-For-Delay Will Kill Innovation
An Abbott Laboratories subsidiary on Tuesday asked the U.S. Supreme Court to consider the Federal Trade Commission's antitrust challenge to "pay-for-delay" drug patent settlements, arguing that impeding such deals will threaten...To view the full article, register now.
Already a subscriber? Click here to view full article